It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory ...

Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Lexicon Pharmaceuticals LXRX in the last three months. The following table summarizes their ...

Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lexicon Pharmaceuticals’ strategic advancements and potential for value growth. One significant reason is the ...

(Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) for sotagliflozin in all markets ...

Daniel Radcliffe once said "the best decision that was ever made for the series" had to do with the third film.

The English Chumash that presents a multitude of interpretations from all generations that sold 10,000 copies in a less than ...

It seemed only fitting to give her a name loosely translating from Hebrew as “my wave of divine ... but also new concepts for her four-year-old lexicon. As the Jewish electorate marks our ...